Galen Patient Recruitment
Galen Patient Recruitment is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis
Sponsor Oruka Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
INCB 18424-319: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Purigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN1)
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
INCB 18424-320: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Prurigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN2)
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
18424-326: A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Galen Patient Recruitment?
The 2026-10-09 snapshot links Galen Patient Recruitment to 9 distinct CTIS trials. Recorded services include Patient Recruitment, Recruitment activities, Recruitment activities in USA and Canada, Recruitment Vendor. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Galen Patient Recruitment?
The most frequently recorded therapeutic areas are Dermatology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Galen Patient Recruitment conducted?
The linked trials record locations in 12 countries, including Germany, Poland, Spain, France, Italy. These are trial locations, not confirmed office locations or countries where Galen Patient Recruitment delivered services.
What can this page tell me about Galen Patient Recruitment's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Galen Patient Recruitment. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Galen Patient Recruitment Inc.